Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD7687 · 2 trials · 4 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| AZD7687 | DRUG | Oral suspension |
| Placebo | DRUG | Oral suspension, once daily. Totally 8 doses |
Inclusion Criteria: * Suitable veins for cannulation or repeated venipuncture * Have a body mass index (BMI) between 19 and 35 kg/m2 and weigh at least 50 kg and no more than 90 kg * Male subjects should be willing to use barrier contraception ie, condoms with spermicide, from the first day of dosi...
AZD7687 was investigated for the treatment of overweight and type 2 diabetes. It is a small molecule developed by AstraZeneca PLC as an oral therapy for metabolic conditions. The clinical program explored its use in overweight and obese adults, including patients with type 2 diabetes, but the drug remains investigational and is not approved for any indication.
AZD7687 targets DGAT1, also known as diacylglycerol O-acyltransferase 1. It is an inhibitor of this enzyme, which plays a role in triglyceride synthesis. By inhibiting DGAT1, AZD7687 was designed to modulate lipid metabolism, a mechanism relevant to metabolic disorders such as obesity and type 2 diabetes.
AZD7687 is being developed by AstraZeneca PLC, which trades on the Nasdaq under the ticker AZN. AstraZeneca sponsored the clinical trials for this small molecule candidate. The company is a global biopharmaceutical firm with a portfolio that includes metabolic and cardiovascular therapies.
AZD7687 is in Phase 1 clinical development. It has completed Phase 1 trials evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy volunteers and patients with type 2 diabetes or obesity. The drug has not advanced beyond Phase 1 and is not approved for any indication.
AZD7687 has been studied in two completed Phase 1 trials: NCT01217905, a Japanese single and multiple ascending dose study in type 2 diabetes and obesity, and NCT01119352, a multiple ascending dose study in overweight and obese participants. Both trials were conducted in the United Kingdom and are now completed.